Antimicrobial Resistance Diagnostics Market Size Projected to Reach $5.07 billion by 2034 | 4.23%

According to Straits Research, the global antimicrobial susceptibility testing market size was valued at $4.59 billion in 2025 and is expected to grow from $4.85 billion in 2026 to $7.55 billion by 2034, registering a CAGR of 5.69% during the forecast period (2026–2034)

Market Dynamics

The global antimicrobial resistance diagnostics market is experiencing steady growth, primarily driven by the rising prevalence of drug-resistant infections worldwide. Increasing misuse and overuse of antibiotics across human health, animal health, and agriculture have accelerated the emergence of resistant pathogens, creating a demand for rapid and accurate diagnostic solutions. Healthcare systems are increasingly prioritizing early detection of resistant organisms to guide appropriate therapy, reduce mortality, and prevent the spread of infections. This has boosted demand for advanced diagnostic technologies such as molecular assays, rapid phenotypic testing, and automated susceptibility testing platforms, particularly in hospitals and reference laboratories.

Despite this strong demand, market growth is restrained by the high cost and infrastructure requirements of advanced AMR diagnostic technologies. Many rapid molecular and automated systems require high upfront investment, skilled laboratory personnel, and well-equipped facilities. These limitations reduce adoption in low income countries, where the burden of antimicrobial resistance is often highest.

On the other hand, a key growth opportunity lies in the development of rapid, cost-effective, and point-of-care AMR diagnostics. Innovations integrating microfluidics, artificial intelligence, and next-generation sequencing are enabling faster results with improved accuracy. As governments and global health organizations strengthen antimicrobial stewardship programs and surveillance initiatives, adoption of such accessible diagnostics is expected to expand, supporting improved patient outcomes and market growth.